Inpharma 1551 - 19 Aug 2006

■ Epratuzumab* combined with rituximab haspromising activity in refractory or recurrent non-Hodgkin’s lymphoma (NHL), according to the resultsof a phase II study. In this open-label study,65 patients with B-cell NHL received epratuzumab360 mg/m2 followed by rituximab 375 mg/m2 weeklyfor 4 consecutive weeks. An objective response wasachieved by 47% of assessable patients, including 22%with complete responses. With a median follow-upduration of 11 months, the median duration ofresponse and progression-free survival were 16 and11 months, respectively, in patients with follicularlymphoma and 6 and 6 months for those with diffuselarge B-cell lymphoma. The researchers point out thatthis therapy was well tolerated, without an increase intoxicity.** Immunomedics; phase II for NHL in the US; and phase III in theUS and phase II in Europe for systemic lupus erythematosus

Strauss SJ, et al. Phase II multicenter trial of epratuzumab, in combinationwith rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. Journal ofClinical Oncology 24: 3880-3886, No. 24, 20 Aug 2006 801017825

1

Inpharma 19 Aug 2006 No. 15511173-8324/10/1551-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved